| Literature DB >> 35656984 |
Li Luo1, Sui-Qing Huang1, Chuang Liu2, Quan Liu1, Shuohui Dong3, Yuan Yue1, Kai-Zheng Liu1, Lin Huang1, Shun-Jun Wang1, Hua-Yang Li1, Shaoyi Zheng4, Zhong-Kai Wu1.
Abstract
Background The early mortality after surgery for infective endocarditis is high. Although risk models help identify patients at high risk, most current scoring systems are inaccurate or inconvenient. The objective of this study was to construct an accurate and easy-to-use prediction model to identify patients at high risk of early mortality after surgery for infective endocarditis. Methods and Results A total of 476 consecutive patients with infective endocarditis who underwent surgery at 2 centers were included. The development cohort consisted of 276 patients. Eight variables were selected from 89 potential predictors as input of the XGBoost model to train the prediction model, including platelet count, serum albumin, current heart failure, urine occult blood ≥(++), diastolic dysfunction, multiple valve involvement, tricuspid valve involvement, and vegetation >10 mm. The completed prediction model was tested in 2 separate cohorts for internal and external validation. The internal test cohort consisted of 125 patients independent of the development cohort, and the external test cohort consisted of 75 patients from another center. In the internal test cohort, the area under the curve was 0.813 (95% CI, 0.670-0.933) and in the external test cohort the area under the curve was 0.812 (95% CI, 0.606-0.956). The area under the curve was significantly higher than that of other ensemble learning models, logistic regression model, and European System for Cardiac Operative Risk Evaluation II (all, P<0.01). This model was used to develop an online, open-access calculator (http://42.240.140.58:1808/). Conclusions We constructed and validated an accurate and robust machine learning-based risk model to predict early mortality after surgery for infective endocarditis, which may help clinical decision-making and improve outcomes.Entities:
Keywords: cardiac surgery; infective endocarditis; machine learning; prognosis; risk model
Mesh:
Year: 2022 PMID: 35656984 PMCID: PMC9238722 DOI: 10.1161/JAHA.122.025433
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 6.106
Figure 1Flow chart of infective endocarditis patients.
FAH‐SYSU indicates the First Affiliated Hospital of Sun Yat‐sen University; and NFH, Nanfang Hospital.
Demographics and Clinical Characteristics of Patients in the Training‐Validation Cohort
| Variable | No./No. (%) |
|---|---|
| Early mortality | 20/276 (7.2) |
| Demographic characteristic | |
| Age, y, mean (SD) [range], y | 43.70 (15.32) [13–84] |
| Age older than 60 y | 50/276 (18.1) |
| Age older than 70 y | 13/276 (4.7) |
| Female sex | 82/276 (29.7) |
| Current smoker | 37/276 (13.4) |
| Medical history | |
| Hypertension | 40/276 (14.5) |
| Coronary heart disease | 13/276 (4.7) |
| Diabetes | 10/276 (3.6) |
| Chronic obstructive pulmonary disease | 4/276 (1.4) |
| Preoperative continuous renal replacement therapy | 3/276 (1.1) |
| Peripheral vascular disease | 9/276 (3.3) |
| Congenital heart disease | 53/276 (19.2) |
| Percutaneous coronary intervention history | 2/276 (0.7) |
| Pacemaker/implantable cardioverter‐defibrillator implantation | 1/276 (0.4) |
| Preoperative cardiac arrest or cardiopulmonary resuscitation | 4/276 (1.4) |
| Recurrence or previous infective endocarditis | 1/276 (0.4) |
| Previous cardiac surgery | 17/276 (6.2) |
| Prosthetic valve endocarditis | 9/276 (3.3) |
| Preoperative mechanical ventilation or respiratory failure | 6/276 (2.2) |
| Preoperative central neurological complications | 63/276 (22.8) |
| Cerebral infarction within 3 mo | 24/276 (8.7) |
| Preoperative embolization event | 76/276 (27.5) |
| Moderate or severe anemia | 46/276 (16.7) |
| Renal insufficiency | 17/276 (6.2) |
| Malnutrition | |
| Moderate | 35/276 (12.7) |
| Severe | 8/276 (2.9) |
| Current heart failure | 47/276 (17.0) |
| Symptom and sign | |
| Atrial fibrillation or atrial flutter | 23/276 (8.3) |
| Cardiac conduction block | 3/276 (1.1) |
| Surgery‐related information | |
| Duration of preoperative treatment, mean (SD)[range], days | 12.83 (8.53) [2–65] |
| Positive preoperative blood culture result | 139/242 (57.4) |
| Biological valve replacement | 61/262 (23.3) |
| Mechanical valve replacement | 201/262 (76.7) |
| Type of operation | |
| Isolated valvuloplasty | 14/276 (5.1) |
| Valve replacement | 262/276 (94.9) |
| Valvuloplasty and valve replacement | 66/276 (23.9) |
| Right‐side heart surgery | 73/276 (26.4) |
| Pulmonary vale | 7/276 (2.5) |
| Valvuloplasty | 3/276 (1.1) |
| Valve replacement | 4/276 (1.4) |
| Tricuspid valve | 66/276 (23.9) |
| Valvuloplasty | 56/276 (20.3) |
| Valve replacement | 10/276 (3.6) |
| Entire heart surgery | 20/276 (7.2) |
Moderate or severe anemia referred to hemoglobin <90 g/L.
Malnutrition was diagnosed based on the serum albumin (ALB) level, moderate malnutrition referred to 25≤ALB <30 g/L, and severe malnutrition referred to ALB <25 g/L.
Current heart failure referred to New York Heart Association class III/IV at admission.
Entire heart surgery referred to the situation in which the patient received both left‐ and right‐side cardiac surgery.
Laboratory Findings and Echocardiographic Characteristics of Patients in the Training‐Validation Cohort
| Variable | Mean (SD) [range] |
|---|---|
| Early mortality, No./No. (%) | 20/276 (7.2) |
| Laboratory finding | |
| White blood cell counts, ×109/L | 8.85 (3.26) [1.72–22.01] |
| Platelet count, ×109/L | 250.43 (93.55) [53–574] |
| Hemoglobin, g/L | 112.99 (24.25) [58–228] |
| Hematocrit, % | 34.31 (6.95) [20.70–71.70] |
| Red cell distribution width, % | 15.38 (2.32) [11–25] |
| N‐terminal pro‐B‐type natriuretic peptide, pg/mL | 2914.37 (10860.59) [16.10–160559.00] |
| Serum creatinine | 91.59 (62.01) [36–602] |
| Renal insufficiency compensation phase, No./No. (%) | 28/276 (10.1) |
| Renal insufficiency decompensated phase, No./No. (%) | 15/276 (5.4) |
| Kidney failure phase, No./No. (%) | 3/276 (1.1) |
| Uremia phase, No./No. (%) | 0/276 (0.0) |
| Blood urea nitrogen, mmol/L | 6.57 (4.55) [2.00–40.60] |
| Uric acid, µmol/L | 379.23 (139.39) [112–798] |
| Serum albumin, g/L | 36.18 (5.53) [20.9–50.2] |
| Total bilirubin, µmol/L | 14.96 (9.79) [1.29–107.60] |
| Aspartate transaminase, U/L | 28.01 (22.41) [4.50–254.00] |
| Fibrin, g/L | 3.78 (1.27) [1.06–7.78] |
| Blood glucose | 5.04 (4.55) [1.4–13.4] |
| Mildly elevated, No./No. (%) | 20/276 (7.2) |
| Moderately elevated, No./No. (%) | 5/276 (1.8) |
| Severely elevated, No./No. (%) | 2/276 (0.7) |
| Urine occult blood ≥ (++), No./No. (%) | 118/265 (44.5) |
| Blood culture result, No./No. (%) | |
| Negative | 103/242 (42.6) |
|
| 44/242 (18.2) |
| Other | 6/242 (2.5) |
|
| 15/242 (6.2) |
| Coagulase‐negative | 2/242 (0.8) |
| Other bacteria | 71/242 (29.3) |
| Fungus | 1/242 (0.4) |
| Echocardiographic characteristic, No./No. (%) | |
| Valve involved | |
| Left heart | 257/276 (93.1) |
| Aortic valve | 141/276 (51.1) |
| Mitral valve | 165/276 (59.8) |
| Aortic and mitral valve | 48/276 (17.8) |
| Right heart | 24/276 (8.7) |
| Pulmonary valve | 8/276 (2.9) |
| Tricuspid valve | 16/276 (5.8) |
| Single valve involved | 221/276 (80.1) |
| Multiple valves involved | 55/276 (19.9) |
| Vegetation formation | 257/276 (93.1) |
| Size of vegetation | 11.20 (7.13) [0–45.00] |
| Larger than 10 mm | 152/276 (55.1) |
| Larger than 15 mm | 88/276 (31.9) |
| Larger than 20 mm | 31/276 (11.2) |
| LVEF, mean (SD)[range], % | 66.77 (8.44) [30–97] |
| LVEF<40% | 2/276 (0.7) |
| Pulmonary artery pressure, mean (SD)[range] | 40.52 (13.63) [16–86] |
| Moderate or higher pulmonary hypertension | 53/276 (19.2) |
| Severe pulmonary hypertension | 16/276 (5.8) |
| Diastolic dysfunction | 174/276 (63.0) |
| Class I | 121/276 (43.8) |
| Class II | 41/276 (14.9) |
| Class III | 12/276 (4.3) |
| Medium or more pericardial effusion | 3/276 (1.1) |
| Heart abscess | 29/276 (10.5) |
| Paravalvular abscess | 23/276 (8.3) |
| Left atrial thrombus | 2/276 (0.7) |
LVEF indicates left ventricular ejection fraction.
Patients with serum creatine levels of 133–177 µmol/L were considered at the renal insufficiency compensation phase, 178–442 µmol/L were considered at renal insufficiency decompensated phase, 443–707 µmol/L were considered at the kidney failure phase, and over 707 µmol/L were considered at the uremia phase.
Fasting blood glucose >7 mmol/L was considered as mildly elevated, >8.4 mmol/L was considered as moderately elevated, and >11.1 mmol/L was considered as severely elevated.
Valve involvement referred to valve affected by infection.
Size of vegetation referred to the largest diameter of vegetation measured by echocardiography.
Figure 2The online calculator* for predicting early mortality after infective endocarditis surgery.
*The Department of Cardiac Surgery of the First Affiliated Hospital of Sun Yat‐sen University is responsible for the online calculator (http://42.240.140.58:1808). SYSUPMIE indicates Sun Yat‐sen University Prediction Model for Infective Endocarditis.
Figure 3Model performance in the test sets.
A through C, ROC analysis of Sun Yat‐sen University Prediction Model for Infective Endocarditis (SYSUPMIE), classic logistic regression model, random forest model, extra trees model, LightGBM model, GBDT model and EuroSCORE II for predicting early mortality after surgery for IE in the internal test set of the First Affiliated Hospital of Sun Yat‐sen University, in the external test set of Nanfang Hospital, and in the integrated test set. D, Calibration curve of SYSUPMIE in the integrated test set. E, Decision curve analysis (DCA) of SYSUPMIE, classic logistic regression, random forest model, extra trees model, LightGBM model, GBDT model and EuroSCORE II based on the integrated test set. AUC indicates area under the curve; EuroSCORE II, European System for Cardiac Operative Risk Evaluation II; ET, extra trees; FAH‐SYSU, First Affiliated Hospital of Sun Yat‐sen University; GBDT, gradient boosting decision trees; LGBM, light gradient boosting machine; LR, logistic regression; RF, random forest; ROC, receiver‐operator characteristic curve; and SY, Sun Yat‐sen University Prediction Model for Infective Endocarditis.
Figure 4Risk stratification and feature contribution analysis for SYSUPMIE.
A, Confusion matrices at cutoffs of 0.35 and 0.055 for the high‐ and low‐risk groups, based on the integrated test set. B, The actual probability of early mortality in low‐, medium‐, and high‐risk groups, based on the integrated test set. C, Relevance of SYSUPMIE risk to early mortality and features. D, Feature contribution analysis, based on the integrated test set. The error bars denote SD of feature contribution. ALB indicates serum albumin; HF, heart failure; PLT, platelet count; SYSUPMIE, Sun Yat‐sen University Prediction Model for Infective Endocarditis; and UOB, urine occult blood.